LS&HC Horizons 2022 - Flipbook - Page 29
Hogan Lovells | 2022 Life Sciences and Health Care Horizons
29
Covid-19 and Pandemic Preparedness
Health security and pandemic preparedness
As the Covid-19 pandemic continues to evolve, we expect life sciences
companies to remain laser focused on health security and pandemic
preparedness. Initiatives targeting existing infectious diseases
including Covid-19, influenza, and HIV and other serious conditions,
readily cross product categories, including therapeutics, vaccines,
diagnostics, devices, and digital health technologies. Similarly,
preemptive medicine initiatives, focused on extending healthy lifespan
and improving the wellbeing of a growing global population, cross
traditional regulatory paradigms and provide new opportunities to
integrate previously siloed interventions (e.g., behavioral, advanced
diagnostics, agricultural biotechnology) to create sustainable solutions
to global challenges.
Moving forward, we see a unique opportunity for emerging companies
and their investors in these cross-functional areas. Early stage
innovators can move quickly to leverage advanced technologies such
as artificial intelligence/machine learning (AI/ML) platforms for early
detection or even to prevent the progression of chronic conditions.
Supply chain resilience will also continue to be front and center
across the life sciences sector. We expect continued investments in
manufacturing capacities, advanced manufacturing, and strategic
onshoring efforts to prevent shortages of essential medicines and
inequitable distribution. Opportunities in plant- and microbial-based
ingredients and processes for food production are also abundant.
Blake Wilson
Partner, Philadelphia
We see additional opportunities for companies to benefit from
strategic and interactive engagement with FDA and other agencies
early in product development allowing innovators to prioritize
investments on scientific, design, manufacturing, or other critical
considerations. FDA likely will continue integrating lessons made
necessary by the current pandemic to streamline review processes
and to advance real-world evidence and patient-generated data to
support or enrich regulatory decision-making. These opportunities
highlight the significance of having, at the outset, a fully integrated
team that understands the science, data, and the law and regulations
that govern them.
We look forward to partnering with our clients as we prepare,
together, for advancing technologies for improved health security.
Lowell Zeta
Partner, Washington, D.C.
Visit our website to learn more
about our Emerging Companies
and Investors work.
